TFF Pharmaceuticals, Inc. (0K3.F)
- GlobeNewswire
TFF Pharmaceuticals to Participate at the H.C. Wainwright Global Investment Conference
FORT WORTH, Texas, May 20, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will be virtually participating in the H.C. Wainwright Global Investment Conference being held May 23 - 26, 2022. Company management will also be participating in virtual one-o
- Zacks
TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Misses Revenue Estimates
TFF Pharmaceuticals, Inc. (TFFP) delivered earnings and revenue surprises of 13.16% and 33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
TFF Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
Announced Collaboration with Catalent to Further Expand Thin Film Freezing Applications with a Focus on Biologic Drug Development Announced Second CRADA Agreement with USAMRIID and Geneva Foundation to Develop Novel Therapies Using Thin Film Freezing to Combat SARS-CoV-2, Ebola, and Marburg Viruses Initiated Phase 2 Trials of Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder With Interim Data for Each Program Expected Later in 2022 Significant Progress Made in Inhaled Niclosamide Powder
